| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Scinderin |
| Entrez GeneID | 85477 |
| WB Predicted band size | Calculated MW: 80 kDa; Observed MW: 80 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic peptide of human SCIN |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3篇与SCIN(Staphylococcal Complement Inhibitor)抗体相关的文献摘要概括：
---
1. **标题**：*Staphylococcal complement inhibitor: structure and mechanism of action*
**作者**：Rooijakkers SHM, et al.
**摘要**：该研究解析了SCIN蛋白的晶体结构，揭示其通过结合补体C3转化酶抑制免疫反应，并利用特异性抗体验证了其功能位点，为靶向治疗提供依据。
2. **标题**：*Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases*
**作者**：Jongerius I, et al.
**摘要**：本文发现SCIN通过阻断补体C3转化酶的活性帮助金黄色葡萄球菌逃避免疫清除，通过抗体验证其在血清中的抑制效果，提出其在感染中的病理意义。
3. **标题**：*Structural basis for complement inhibition by Staphylococcus aureus*
**作者**：Garcia BL, et al.
**摘要**：结合冷冻电镜和抗体标记技术，阐明SCIN与补体蛋白的相互作用机制，证实其通过稳定C3转化酶构象抑制宿主防御，为抗感染药物设计提供新思路。
---
以上文献均聚焦于SCIN蛋白的结构、功能及抗体应用研究，相关论文可从PubMed或专业学术数据库获取全文。
SCIN (Staphylococcal Complement Inhibitor) is a secreted protein produced by *Staphylococcus aureus*, a major human pathogen. It plays a critical role in immune evasion by inhibiting the complement system, a key component of the host innate immune response. SCIN specifically targets the C3 convertase complex (C4b2a/C3bBb), stabilizing it in an inactive state and preventing the cleavage of C3 into bioactive fragments (C3a/C3b). This blockade disrupts downstream complement pathways, including opsonization, inflammatory mediator release, and membrane attack complex (MAC) formation, thereby reducing bacterial clearance by phagocytes and enhancing *S. aureus* survival in host tissues.
SCIN antibodies are developed to neutralize this virulence factor, either for research or therapeutic purposes. In research, anti-SCIN antibodies help elucidate the molecular mechanisms of complement inhibition and bacterial immune evasion. Therapeutically, they are explored as adjuncts to antibiotics to boost host immunity against drug-resistant *S. aureus* infections. Studies also suggest SCIN antibodies could aid in vaccine design by targeting conserved epitopes to induce protective immunity. Understanding SCIN-antibody interactions provides insights into novel anti-infective strategies against persistent staphylococcal infections.
(Word count: 195)
×
